Home Alzheimer’s Disease In Papillary RCC, Cabozantinib Bests Sunitinib for PFS

In Papillary RCC, Cabozantinib Bests Sunitinib for PFS

Patients with metastatic papillary renal cell carcinoma treated in a phase 2 trial had statistically significant and clinically meaningful improvements in progression-free survival (PFS) with cabozantinib (Cabometyx) versus sunitinib (Sutent), resulting in a 40% reduction in the risk of disease progression or death and achievement of the trials primary end point.

These results were taken from the randomized SWOG 1500 study (NCT02761057) that were presented during the 2021 Genitourinary Cancers Symposium. The median PFS with cabozantinib was 9.0 months versus 5.6 months with sunitinib (HR 0.60; 95% CI, 0.37-0.97; 1-sided P = .019).

The agent also significantly higher response rate relative to sunitinib, at 23% versus 4.0%, respectively, in this population (2-sided P = .010). Complete responses were only observed among those who were given cabozantinib. Moreover, although sunitinib was also…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments